Afamin - A pleiotropic glycoprotein involved in various disease states

Clinica Chimica Acta

Volumn 446, Issue , 2015, Pages 105-110

  Dieplinger, Hans ^a,b   Dieplinger, Benjamin ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Vitateq Biotechnology GmbH   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Diagnosis; Metabolic syndrome; Neuroprotection; Pregnancy; Prognosis; Tumor marker

Indexed keywords

AFAMIN; GLYCOPROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; AFM PROTEIN, HUMAN; ALPHA TOCOPHEROL; BIOLOGICAL MARKER; CARRIER PROTEIN; SERUM ALBUMIN;

ALZHEIMER DISEASE; BLADDER CARCINOMA; BLOOD BRAIN BARRIER; BODY FLUID; BREAST CARCINOMA; COLORECTAL CARCINOMA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; MASS SPECTROMETRY; METABOLIC SYNDROME X; MOLECULAR WEIGHT; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATHOGENESIS; PHENOTYPE; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; PROTEIN STRUCTURE; REVIEW; STOMACH CARCINOMA; THYROID CANCER; UTERINE CERVIX CARCINOMA; ANIMAL; BLOOD; METABOLIC DISEASES; METABOLISM; SEVERITY OF ILLNESS INDEX;

MUS MUSCULUS;

ANIMALS; BIOMARKERS; BLOOD-BRAIN BARRIER; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; METABOLIC DISEASES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; VITAMIN E;

EID: 84928349017     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.04.010     Document Type: Review

References (41)

1. Lichenstein H.S., Lyons D.E., Wurfel M.M., et al. Afamin is a new member of the albumin, a-fetoprotein, and vitamin D-binding protein gene family. J Biol Chem 1994, 269:18149-18154.
2. Bélanger L., Roy S., Allard D. New albumin gene 3' adjacent to the a1-fetoprotein locus. J Biol Chem 1994, 269:5481-5484.
3. Araki T., Haupt H., Hermentin P., et al. Preparation and partial structural characterization of alpha1T-glycoprotein from normal human plasma. Arch Biochem Biophys 1998, 351:250-256.
4. Haupt H., Heide K. Isolation of several tryptophan-poor alpha 1-glycoproteins occurring in traces from human serum. Clin Chim Acta 1964, 10:555-558.
5. Nishio H., Heiskanen M., Palotie A., Belanger L., Dugaiczyk A. Tandem arrangement of the human serum albumin multigene family in the sub-centromeric region of 4q: evolution and chromosomal direction of transcription. J Mol Biol 1996, 259:113-119.
6. Naidu S., Peterson M.L., Spear B.T. Alpha-fetoprotein related gene (ARG): a new member of the albumin gene family that is no longer functional in primates. Gene 2010, 449:95-102.
7. Nishio H., Dugaiczyk A. Complete structure of the human alpha-albumin gene, a new member of the serum albumin multigene family. Proc Natl Acad Sci U S A 1996, 93:7557-7561.
8. Jerkovic L., Voegele A.F., Chwatal S., et al. Afamin is a novel human vitamin E-binding glycoprotein characterization and in vitro expression. J Proteome Res 2005, 4:889-899.
9. Allard D., Gilbert S., Lamontagne A., Hamel D., Belanger L. Identification of rat a-albumin and cDNA cloning of its human ortholog. Gene 1995, 15:287-288.
10. Jin L., Long L., Green M.A., Spear B.T. The alpha-fetoprotein enhancer region activates the albumin and alpha-fetoprotein promoters during liver development. Dev Biol 2009, 336:294-300.
11. Liu H., Ren H., Spear B.T. The mouse alpha-albumin (afamin) promoter is differentially regulated by hepatocyte nuclear factor 1alpha and hepatocyte nuclear factor 1beta. DNA Cell Biol 2011, 30:137-147.
12. Liu J., Walp E.R., May C.L. Elevation of transcription factor Islet-1 levels in vivo increases beta-cell function but not beta-cell mass. Islets 2012, 4:199-206.
13. Voegele A.F., Jerkovic L., Wellenzohn B., et al. Characterization of the vitamin E-binding properties of human plasma afamin. Biochemistry 2002, 41:14532-14538.
14. Kayden H.J., Traber M.G. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res 1993, 34:343-358.
15. Fanali G., Fasano M., Ascenzi P., Zingg J.M., Azzi A. Alpha-tocopherol binding to human serum albumin. Biofactors 2013, 39:294-303.
16. Dieplinger B., Egger M., Gabriel C., et al. Analytical characterization and clinical evaluation of an enzyme-linked immunosorbent assay for measurement of afamin in human plasma. Clin Chim Acta 2013, 425:236-241.
17. Dieplinger H., Ankerst D.P., Burges A., et al. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009, 18:1127-1133.
18. Jackson D., Craven R.A., Hutson R.C., et al. Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer. Clin Cancer Res 2007, 13:7370-7379.
19. Kronenberg F., Kollerits B., Kiechl S., et al. Plasma concentrations of afamin are associated with the prevalence and development of metabolic syndrome. Circ Cardiovasc Genet 2014, 7:822-829.
20. Kratzer I., Bernhart E., Wintersperger A., et al. Afamin is synthesized by cerebrovascular endothelial cells and mediates alpha-tocopherol transport across an in vitro model of the blood-brain barrier. J Neurochem 2009, 108:707-718.
21. Heiser M., Hutter-Paier B., Jerkovic L., et al. Vitamin E binding protein afamin protects neuronal cells in vitro. J Neural Transm Suppl 2002, 337-345.
22. Kim B.J., Lee Y.S., Lee S.Y., et al. Afamin secreted from nonresorbing osteoclasts acts as a chemokine for preosteoblasts via the Akt-signaling pathway. Bone 2012, 51:431-440.
23. Kim B.J., Lee Y.S., Lee S.Y., et al. Afamin stimulates osteoclastogenesis and bone resorption via Gi-coupled receptor and Ca2+/calmodulin-dependent protein kinase (CaMK) pathways. J Endocrinol Invest 2013, 36:876-882.
24. Melmer A., Fineder L., Lamina C., et al. Plasma concentrations of the vitamin E-binding protein afamin are associated with overall and progression-free survival and platinum sensitivity in serous ovarian cancer - a study by the OVCAD consortium. Gynecol Oncol 2013, 128:38-43.
25. Seeber B.E., Czech T., Buchner H., et al. The vitamin E-binding protein afamin is altered significantly in the peritoneal fluid of women with endometriosis. Fertil Steril 2010, 94:2923-2926.
26. Aktas B., Kasimir-Bauer S., Wimberger P., Kimmig R., Heubner M. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer. Anticancer Res 2013, 33:329-336.
27. Chen Y.T., Chen H.W., Domanski D., et al. Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J Proteomics 2012, 75:3529-3545.
28. Choi J.W., Liu H., Shin D.H., et al. Proteomic and cytokine plasma biomarkers for predicting progression from colorectal adenoma to carcinoma in human patients. Proteomics 2013, 13:2361-2374.
29. Humphries J.M., Penno M.A., Weiland F., et al. Identification and validation of novel candidate protein biomarkers for the detection of human gastric cancer. Biochim Biophys Acta 1844, 2014:1051-1058.
30. Jeong D.H., Kim H.K., Prince A.E., et al. Plasma proteomic analysis of patients with squamous cell carcinoma of the uterine cervix. J Gynecol Oncol 2008, 19:173-180.
31. Opstal-van Winden A.W., Krop E.J., Karedal M.H., et al. Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study. BMC Cancer 2011, 11:381.
32. Song H.J., Xue Y.L., Qiu Z.L., Luo Q.Y. Comparative serum proteomic analysis identified afamin as a downregulated protein in papillary thyroid carcinoma patients with non-131I-avid lung metastases. Nucl Med Commun 2013, 34:1196-1203.
33. Penno M.A., Klingler-Hoffmann M., Brazzatti J.A., et al. 2D-DIGE analysis of sera from transgenic mouse models reveals novel candidate protein biomarkers for human gastric cancer. J Proteomics 2012, 77:40-58.
34. Ringman J.M., Schulman H., Becker C., et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 2012, 69:96-104.
35. Rosenling T., Stoop M.P., Attali A., et al. Profiling and identification of cerebrospinal fluid proteins in a rat EAE model of multiple sclerosis. J Proteome Res 2012, 11:2048-2060.
36. Song F., Poljak A., Kochan N.A., et al. Plasma protein profiling of mild cognitive impairment and Alzheimer's disease using iTRAQ quantitative proteomics. Proteome Sci 2014, 12:5.
37. Hubalek M., Buchner H., Mortl M.G., et al. The vitamin E-binding protein afamin increases in maternal serum during pregnancy. Clin Chim Acta 2014, 434:41-47.
38. Basaran A. Pregnancy-induced hyperlipoproteinemia: review of the literature. Reprod Sci 2009, 16:431-437.
39. Koninger A., Edimiris P., Koch L., et al. Serum concentrations of afamin are elevated in patients with polycystic ovary syndrome. Endocr Connect 2014, 3:120-126.
40. Seeber B., Morandell E., Lunger F., Wildt L., Dieplinger H. Afamin serum concentrations are associated with insulin resistance and metabolic syndrome in polycystic ovary syndrome. Reprod Biol Endocrinol 2014, 12:88.
41. Percy A.J., Chambers A.G., Yang J., Hardie D.B., Borchers C.H. Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. Biochim Biophys Acta 1844, 2014:917-926.